Tag Archives: Lilly

December, 2018

November, 2018

October, 2018

September, 2018

  • 28 September

    Lilly’s Emgality Receives FDA Approval for the Prevention of Migraine in Adults

    INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ — Eli Lilly and Company(NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.1 Emgality offers a once-monthly, self-administered, subcutaneous injection.1 Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.1 …

July, 2018

June, 2018